Treatment with bupropion and varenicline for smoking cessation and the risk of acute cardiovascular events and injuries: a Swedish case-crossover study (original) (raw)

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2017

Abstract

Bupropion and varenicline are non-nicotine medications used for smoking cessation that mitigate craving and withdrawal symptoms. We aim to investigate whether these drugs increase the risk of selected acute adverse outcomes when used in medical practice. Population-based case-crossover design using data from Swedish health and administrative registers. Adult individuals diagnosed with acute myocardial infarction, stroke, suicide, suicide attempt, fall injury, or that suffered a road traffic crash from 01.10.2006 for bupropion, or from 01.03.2008 for varenicline, until 31.12.2013 were included. Different lengths of exposure periods were analyzed within the twelve-week hazard period prior to the adverse outcome (1-14, 15-28, and 29-84 days). The control period was matched using the interval preceding the hazard period (85-168 days), and breaking it up into equivalent periods (85-98, 99-112, and 113-168 days). Conditional logistic regression with each case considered as one stratum was...

Maria Galanti hasn't uploaded this paper.

Let Maria know you want this paper to be uploaded.

Ask for this paper to be uploaded.